1. Signaling Pathways
  2. Vitamin D Related/Nuclear Receptor
  3. Orphan Nuclear Receptor
  4. Orphan Nuclear Receptor Antagonist

Orphan Nuclear Receptor Antagonist

Orphan Nuclear Receptor Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-108469
    BI-6015
    Antagonist 99.90%
    BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes.
  • HY-149913
    NR2F1 agonist 1
    Antagonist 99.06%
    NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model.
  • HY-135589
    7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene
    Antagonist 98.52%
    7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is a liver receptor homolog-1 (LRH-1) antagonist with an IC50 of 3.1 μM.
  • HY-159920
    PSB-22269
    Antagonist
    PSB-22269 is a GPR17 antagonist with a Ki value of 8.91 nM. PSB-22269 further demonstrated significant inhibitory effects in cAMP and G protein activation assays. Molecular docking studies revealed that the binding site of PSB-22269 contains positively charged arginine residues and a hydrophobic pocket. PSB-22269 provides a strategy to promote remyelination and holds promise for research in the field of multiple sclerosis.
  • HY-148259
    SF-1 antagonist-1
    Antagonist
    SF-1 antagonist-1 (compound 11) is a antagonist of steroidogenic factor 1 (SF-1). SF-1 antagonist-1 affects SF-1 transcriptional activity with an EC50 value of <200 nM. SF-1 antagonist-1 inhibits the proliferation of Rat Leydig tumor cells. SF-1 antagonist-1 can be used for the research of cancer.